Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

By Dave Fornell, DAIC editor

The Cardiovascular Research Foundation’s Transcatheter Cardiovascular Therapeutics (TCT) 2013 meeting brought many new insights about the latest cardiovascular technologies and treatment techniques. Among the hottest topics were transcatheter heart valve repairs, renal denervation to treat drug resistant hypertension, left atrial appendage (LAA) occluders to prevent stroke and eliminate warfarin therapy in atrial fibrillation patients, bifurcation stenting trials and techniques, new insights on anti-clotting agents, increasing use of ultrasound and intravascular imaging, new technologies for FFR lesion assessments, and the latest stent trial data.

I offer my editor’s choice for the most innovative new technologies presented in sessions and on the show floor in a video format.

For a video of the top meeting highlights, Herb Aronow, M.D., offers his views on some of the most interesting topics discussed in sessions.

The most exciting interventional device to enter the U.S. market a couple days prior to TCT was Abbott's MitraClip. We conducted a video interview with the lead author of the MitraClip FDA pivotal trial at TCT.

Here is a summary of some of the top news from TCT. You can click on any item to read the full story.

CoreValve shows outcomes as good or better that Sapien

CT-FFR shown to be comparable to invasive FFR

Dedicated Tryton bifurcation stent did not meet primary endpoint

Provisional vs. two-stent bifurcation therapy has similar outcomes

Data promising for first FDA drug-eluting balloon trial

Simplified, non-adenosine iFR compares favorably with standard FFR

Hypothermia for STEMI safe, but did not reduce infarct size

Thrombectomy does not improve outcomes in NSTEMI PCI

MitraClip trial data leads to FDA approvalVideo interview with lead author of study

Bioresorbable polymer coated stent equal to traditional DES

Boston Scientific’s Lotus TAVR valve meets primary endpoints in REPRISE II

Pre-hospital bivalirudin for STEMI improves outcomes

• Data from two trials (ARCTIC-INTERRUPTION and OPTIMIZE) shows short-duration DAPT is feasible

Genetic profiling for CYP2C19 antiplatelet agents improves outcomes

Transradial access lowers bleeding risks in women

In addition to these news items, listed below are more top trial summaries and new product releases.


Related Content

News | Left Atrial Appendage (LAA) Occluders

May 25, 2023 — Boston Scientific Corporation announced data supporting use of the company's key electrophysiology and ...

Home May 25, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

May 22, 2023 — Boston Scientific Corporation announced data supporting use of the company's key electrophysiology and ...

Home May 22, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

March 28, 2023 — The Society for Cardiovascular Angiography and Interventions (SCAI) and the Heart Rhythm Society (HRS) ...

Home March 28, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

February 27, 2023 — Conformal Medical, Inc. announced today the results from the CONFORMAL Early Feasibility Study (EFS) ...

Home February 27, 2023
Home
News | Left Atrial Appendage (LAA) Occluders

December 22, 2022 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac ...

Home December 22, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

September 12, 2022 — Boston Scientific Corporation has received U.S. Food and Drug Administration (FDA) approval to ...

Home September 12, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

June 27, 2022 — Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias ...

Home June 28, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

April 12, 2022 – Patients who had leakage to the left atrial appendage due to incomplete device sealing after left ...

Home April 12, 2022
Home
News | Left Atrial Appendage (LAA) Occluders
February 28, 2022 – Boston Scientific Corporation has announced positive results from a new analysis assessing real ...
Home February 28, 2022
Home
News | Left Atrial Appendage (LAA) Occluders

November 8, 2021 – SWISS-APERO is the first randomized clinical trial comparing the Abbott Amulet left atrial appendage ...

Home November 08, 2021
Home
Subscribe Now